News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CSPC PHARMA (01093.HK) Ustekinumab Injection Approved for Market Launch
CSPC PHARMA (01093.HK) announced that the Groups self-developed ustekinumab injection, marketed under the brand name Enyike, has been approved for market launch by the National Me...
Reset
Send
The window will close in 5 seconds
CSPC PHARMA (01093.HK) Ustekinumab Injection Approved for Market Launch
Close
Recommend
4
Positive
7
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CSPC PHARMA (01093.HK)  +0.540 (+7.759%)    Short selling $350.44M; Ratio 20.191%   announced that the Groups self-developed ustekinumab injection, marketed under the brand name Enyike, has been approved for market launch by the National Medical Products Administration.

The originator drug Stelara (ustekinumab injection) was approved for launch in China in 2017 and has been approved in China for three indications: adult plaque psoriasis, pediatric plaque psoriasis and Crohns disease. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)

Related NewsCSPC PHARMA (01093.HK) 1Q26 Basic Profit Falls 40.3% YoY to RMB842 million

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.